MERRION CAPITAL recently ran the slide rule over Kerry Group and decided that its earnings potential for the next while would remain constrained.

GREENCORE will get just €100 million of the €146m earmarked for the industry through the EU’s compensation fund.

ELAN and Biogen’s new multiple sclerosis drug, Tysabri, will be priced 30% dearer than expectations lifting the prospects of Elan returning to profitability in 2006.

ELAN is finally emerging from the confidence crisis that hit the company in 2002, resulting in a massive fall in its share price, with the announcement of a settlement with the US Securities and Exchange Commission.